Clinical trial · Interventional
Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 5-HT3 receptor antagonist (e.g., ondansetron) | Drug | — | UNRESOLVED |
| Acupoint application | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acupoint application plus 5-HT3 receptor antagonist
- description
- Participants receive herbal acupoint plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis before and during one cycle of platinum-based chemotherapy.
- interventionNames
- Drug: 5-HT3 receptor antagonist (e.g., ondansetron)
- Other: Acupoint application
- type
- ACTIVE_COMPARATOR
- label
- 5-HT3 receptor antagonist alone
- description
- Participants receive standard 5-HT3 receptor antagonist prophylaxis alone before and during one cycle of platinum-based chemotherapy.
- interventionNames
- Drug: 5-HT3 receptor antagonist (e.g., ondansetron)
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically or cytologically confirmed lung cancer. * Scheduled to receive first-line platinum-based chemotherapy. * Aged 18 to 75 years. * Karnofsky Performance Status (KPS) score ≥ 60. * Expected survival ≥ 3 months. * Voluntarily signed written informed consent. Exclusion Criteria: * Known allergy to any component of the acupoint plaster. * Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women. * Cognitive impairment or psychiatric disorder that prevents completion of study assessments. * Participation in another interventional clinical trial within 30 days prior to enrollment.
References
Publications (0)
Data not yet available